Progressive dementia with neuroserpin inclusion bodies Advocacy Hub | UniteRare

At a Glance

Live from database

Regulatory Watchboard

1 event

Dec 2021

Tarpeyo: FDA approved

to reduce proteinuria in adults with primary immunoglobulin A nephropathy (IgAN) at risk of rapid disease progression, generally a urine protein-to-creatinine ratio (UPCR) > or = 1.5 g/g

FDAcompleted

Data from FDA regulatory filings and ClinicalTrials.gov. Updated periodically.

Financial Assistance

FINANCIAL LANDSCAPE SUMMARY

Total programs

No financial assistance programs currently listed for Progressive dementia with neuroserpin inclusion bodies.
Check the disease page for updates →

Approved Treatments

1 FDA-approved

Tarpeyo

(budesonide delayed-release)Orphan drug

Calliditas Therapeutics

Corticosteroid [EPC]

12.1 Mechanism of Action Budesonide is a corticosteroid with potent glucocorticoid activity and weak mineralocorticoid activity that undergoes substan...

Approved Dec 2021FDA label ↗

View full treatment details on disease page →